CBDY Target Group Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1586554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY-155.4%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR40.5%
Net income 3-yr CAGR—
Margins
Gross margin42.0%
Operating margin—
Net margin-30.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-24.6%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets245.5%
Debt / equity—
Current ratio0.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.88M | $6.59M | $3.72M | $0 | $0 |
| Cost of revenue | $1.81M | $2.87M | $2.07M | $0 | — |
| Gross profit | $2.07M | $3.73M | $1.66M | $0 | — |
| Interest expense | $1.04M | $1.15M | $1.41M | $1.12M | $985,634 |
| Pretax income | -$1.36M | $160,504 | -$323,670 | -$4.52M | $272,881 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.36M | $160,504 | -$323,670 | -$4.52M | $272,881 |
| EPS (basic) | -0.00 | 0.00 | -0.00 | -0.01 | 0.00 |
| EPS (diluted) | -0.00 | 0.00 | -0.00 | -0.01 | 0.00 |
| Weighted avg. shares (diluted) | 617.03M | 727.23M | 617.03M | 617.03M | 595.35M |
| Balance sheet | |||||
| Cash & equivalents | $108,800 | $1.88M | $745,019 | $232,333 | $122,151 |
| Receivables | $446,283 | $77,092 | $1.03M | $2,068 | $2,068 |
| Inventory | $1.67M | $882,279 | $1.22M | $0 | $99,000 |
| Current assets | $2.33M | $3.10M | $3.09M | $909,987 | $584,222 |
| PP&E, net | $3.55M | $4.19M | $5.43M | $5.55M | $6.84M |
| Goodwill | $260,016 | $247,685 | $269,460 | $263,117 | $3.68M |
| Total assets | $6.18M | $7.57M | $8.84M | $7.57M | $13.06M |
| Current liabilities | $13.38M | $13.10M | $14.59M | $6.93M | $4.04M |
| Short-term debt | $7.60M | $7.24M | $7.88M | $1.74M | $601,641 |
| Long-term debt | $7.60M | $7.24M | $7.88M | $5.96M | $7.76M |
| Total debt | $15.21M | $14.49M | $15.76M | $7.69M | $8.36M |
| Total liabilities | $14.24M | $14.08M | $15.81M | $14.13M | $15.22M |
| Shareholders' equity | -$8.06M | -$6.51M | -$6.97M | -$6.56M | -$2.15M |
| Net debt | $15.10M | $12.61M | $15.02M | $7.46M | $8.24M |
| Shares outstanding | 617.03M | 617.03M | 617.03M | 617.03M | 617.03M |
| Cash flow statement | |||||
| Operating cash flow | -$842,425 | $2.16M | -$589,612 | -$1.01M | $100,118 |
| Investing cash flow | $81,379 | -$178,978 | $416,932 | $1.02M | -$1.41M |
| Financing cash flow | -$1.06M | -$730,225 | $666,900 | $122,674 | $1.25M |
| Depreciation & amortization | $898,403 | $916,213 | $811,649 | $885,229 | $971,524 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.